Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer

References

• Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121:3786-8; PMID:21965334; http://dx.doi.org/10.1172/JCI60534
   PubMed Web of Science ®Google Scholar
• Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36:206-15; PMID:20060649; http://dx.doi.org/10.1016/j.ctrv.2009.12.002
   PubMed Web of Science ®Google Scholar
• Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6:1329-35; PMID:25276378; http://dx.doi.org/10.3978/j.issn.2072-1439.2014.08.13
   PubMedGoogle Scholar
• Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009; 41:40-7; PMID:19089739; http://dx.doi.org/10.1080/00313020802563510
   PubMed Web of Science ®Google Scholar
• Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, Gonzalez-Angulo AM, Bargallo E, Aguilar JL, et al.. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011; 117:3658-69; PMID:21387260; http://dx.doi.org/10.1002/cncr.25961
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Russo AL, Arvold ND, Niemierko A, Wong N, Wong JS, Bellon JR, Punglia RS, Golshan M, Troyan SL, Brock JE, et al.. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2013; 140:353-61; PMID:23836011; http://dx.doi.org/10.1007/s10549-013-2627-6
   PubMed Web of Science ®Google Scholar
• Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al.. Landscape of transcription in human cells. Nature 2012; 489:101-8; PMID:22955620; http://dx.doi.org/10.1038/nature11233
   PubMed Web of Science ®Google Scholar
• Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med 2012; 10:103; PMID:22613733; http://dx.doi.org/10.1186/1479-5876-10-103
   PubMed Web of Science ®Google Scholar
• Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23:1494-504; PMID:19571179; http://dx.doi.org/10.1101/gad.1800909
   PubMed Web of Science ®Google Scholar
• Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014; 15:7-21; PMID:24296535; http://dx.doi.org/10.1038/nrg3606
   PubMed Web of Science ®Google Scholar
• Hauptman N, Glavac D. Long Non-Coding RNA in Cancer. Int J Mol Sci 2013; 14:4655-69; PMID:23443164; http://dx.doi.org/10.3390/ijms14034655
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861-74; PMID:22094949; http://dx.doi.org/10.1038/nrg3074
   PubMed Web of Science ®Google Scholar
• Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, Ru K, Mercer TR, Thompson ER, Lakhani SR, et al.. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. RNA 2011; 17:878-91; PMID:21460236; http://dx.doi.org/10.1261/rna.2528811
   PubMed Web of Science ®Google Scholar
• Hu P, Yang J, Hou Y, Zhang H, Zeng Z, Zhao L, Yu T, Tang X, Tu G, Cui X, et al.. LncRNA expression signatures of twist-induced epithelial-to-mesenchymal transition in MCF10A cells. Cell Signal 2014; 26:83-93; PMID:24113349; http://dx.doi.org/10.1016/j.cellsig.2013.10.001
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhu Z, Watabe K, Zhang X, Bai C, Xu M, Wu F, Mo YY. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ 2013; 20:1558-68; PMID:23933812; http://dx.doi.org/10.1038/cdd.2013.110
   PubMed Web of Science ®Google Scholar
• Augoff K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 2012; 11:5; PMID:22289355; http://dx.doi.org/10.1186/1476-4598-11-5
   PubMed Web of Science ®Google Scholar
• Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J, Hondermarck H, Curgy JJ, Dugimont T, Adriaenssens E. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 2005; 280:29625-36; PMID:15985428; http://dx.doi.org/10.1074/jbc.M504033200
   PubMed Web of Science ®Google Scholar
• Bhan A, Hussain I, Ansari KI, Kasiri S, Bashyal A, Mandal SS. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol 2013; 425:3707-22; PMID:23375982; http://dx.doi.org/10.1016/j.jmb.2013.01.022
   PubMed Web of Science ®Google Scholar
• Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, Larsen MJ, Kruse TA. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013; 142:529-36; PMID:24258260; http://dx.doi.org/10.1007/s10549-013-2776-7
   PubMed Web of Science ®Google Scholar
• Gupta R, Shah N, Wang K, Kim J, Horlings H, Wong D, Tsai M, Hung T, Argani P, Rinn J, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-6; PMID:20393566; http://dx.doi.org/10.1038/nature08975
   PubMed Web of Science ®Google Scholar
• Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, Mo YY. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 2014; 5:e1008; PMID:24457952; http://dx.doi.org/10.1038/cddis.2013.541
   PubMed Web of Science ®Google Scholar
• Mourtada-Maarabouni M, Pickard M, Hedge V, Farzaneh F, Williams G. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28:195-208; PMID:18836484; http://dx.doi.org/10.1038/onc.2008.373
   PubMed Web of Science ®Google Scholar
• Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A, Liu H, Chen X, Wu J, Lou Y, et al.. A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 2014; 87:254-83; PMID:24184505; http://dx.doi.org/10.1016/j.bcp.2013.10.020
   PubMed Web of Science ®Google Scholar
• Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol 2011; 226:1741-9; PMID:21506106; http://dx.doi.org/10.1002/jcp.22503
   PubMed Web of Science ®Google Scholar
• Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer 2012; 107:947-55; PMID:22892392; http://dx.doi.org/10.1038/bjc.2012.351
   PubMed Web of Science ®Google Scholar
• Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, et al.. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 2013; 4:1748-62; PMID:24077681
   PubMedGoogle Scholar
• Torring PM, Larsen MJ, Kjeldsen AD, Ousager LB, Tan Q, Brusgaard K. Long non-coding RNA expression profiles in hereditary haemorrhagic telangiectasia. PLoS One 2014; 9:e90272; PMID:24603890; http://dx.doi.org/10.1371/journal.pone.0090272
   PubMedGoogle Scholar
• Theurillat JP, Zurrer-Hardi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, et al.. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1723-31; PMID:17410359; http://dx.doi.org/10.1007/s00262-007-0316-1
   PubMed Web of Science ®Google Scholar
• Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer. Hum Mol Genet 2010; 19:R152-61; PMID:20729297; http://dx.doi.org/10.1093/hmg/ddq353
   PubMed Web of Science ®Google Scholar
• Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research. Oncogene 2012; 31:4577-87; PMID:22266873; http://dx.doi.org/10.1038/onc.2011.621
   PubMed Web of Science ®Google Scholar
• Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, Qu LH. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010; 52:1431-42; PMID:20842632; http://dx.doi.org/10.1002/hep.23818
   PubMed Web of Science ®Google Scholar
• Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al.. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007; 447:799-816; PMID:17571346; http://dx.doi.org/10.1038/nature05874
   PubMed Web of Science ®Google Scholar
• Mercer T, Dinger M, Mattick J. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10:155-9; PMID:19188922; http://dx.doi.org/10.1038/nrg2521
   PubMed Web of Science ®Google Scholar
• Mattick J, Makunin I. Non-coding RNA. Hum Mol Genet 2006; 15 Spec No 1:29; PMID:16651366; http://dx.doi.org/10.1093/hmg/ddl046
   PubMed Web of Science ®Google Scholar
• Pauli A, Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, Fan L, Sandelin A, Rinn JL, Regev A, et al.. Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. Genome Res 2012; 22:577-91; PMID:22110045; http://dx.doi.org/10.1101/gr.133009.111
   PubMed Web of Science ®Google Scholar
• Ponting C, Oliver P, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136:629-41; PMID:19239885; http://dx.doi.org/10.1016/j.cell.2009.02.006
   PubMed Web of Science ®Google Scholar
• Harries LW. Long non-coding RNAs and human disease. Biochem Soc Trans 2012; 40:902-6; PMID:22817756; http://dx.doi.org/10.1042/BST20120020
   PubMed Web of Science ®Google Scholar
• Nissan A, Jager D, Roystacher M, Prus D, Peretz T, Eisenberg I, Freund HR, Scanlan M, Ritter G, Old LJ, et al.. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer 2006; 94:681-5; PMID:16495929; http://dx.doi.org/10.1038/sj.bjc.6602992
   PubMed Web of Science ®Google Scholar
• Jiang Y, Harlocker SL, Molesh DA, Dillon DC, Stolk JA, Houghton RL, Repasky EA, Badaro R, Reed SG, Xu J. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene 2002; 21:2270-82; PMID:11948410; http://dx.doi.org/10.1038/sj.onc.1205278
   PubMed Web of Science ®Google Scholar
• Zehentner BK, Dillon DC, Jiang Y, Xu J, Bennington A, Molesh DA, Zhang X, Reed SG, Persing D, Houghton RL. Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 2002; 48:1225-31; PMID:12142378
   PubMed Web of Science ®Google Scholar
• O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol 2007; 28:312-7; PMID:18253069; http://dx.doi.org/10.1159/000115527
   PubMed Web of Science ®Google Scholar
• Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old LJ, Knuth A, Jager D, et al.. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 2006; 12:2745-51; PMID:16675566; http://dx.doi.org/10.1158/1078-0432.CCR-05-2192
   PubMed Web of Science ®Google Scholar
• Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target. Nat Rev Cancer 2010; 10:871-7; PMID:21048784; http://dx.doi.org/10.1038/nrc2933
   PubMed Web of Science ®Google Scholar
• Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011; 21:42-9; PMID:21145726; http://dx.doi.org/10.1016/j.gde.2010.10.011
   PubMed Web of Science ®Google Scholar
• HADFIELD G. The dormant cancer cell. Br Med J 1954; 2:607-10; PMID:13190204
   PubMed Web of Science ®Google Scholar
• Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005; 16:1449-57; PMID:15956037; http://dx.doi.org/10.1093/annonc/mdi280
   PubMed Web of Science ®Google Scholar
• Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006; 13:1033-67; PMID:17158753; http://dx.doi.org/10.1677/ERC-06-0001
   PubMed Web of Science ®Google Scholar
• Balafoutas D, zur HA, Mayer S, Hirschfeld M, Jaeger M, Denschlag D, Gitsch G, Jungbluth A, Stickeler E. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 2013; 13:271; PMID:23731661; http://dx.doi.org/10.1186/1471-2407-13-271
   PubMed Web of Science ®Google Scholar